Docetaxel with prednisone or prednisolone for the treatment of ...

More documents

Recommendations

Info

150 Appendix 6 Study details and Participant details Intervention details Results Conclusion and design comments Survival curve by PSA reduction available; median survival: ≥ 50% or ≥ 80% reduction: 20.5 months
Study details and Participant details Intervention details Results Conclusion and design comments 51 who did not have post-baseline QoL assessments tended to have a poorer performance status and lower QOL at baseline Differencea p-Value Blinding Outcome assessor: No Carer: No Patient: No Success assessed: NA 80% Follow-up: Yes FLIC: total –4.34 0.12 Symptom distress: total 0.05 0.96 Sexual and urological function: total 0.08 0.89 Problems in daily life –1.25 0.20 Impact of pain –1.87 0.38 FLIC: physical well–being –1.90 0.29 FLIC: emotional state –1.42 0.04 FLIC: family disruption –0.93 0.02 FLIC: pain from cancer 0.35 0.26 FLIC: pain interferes –0.18 0.43 Symptom distress: pain, how often –0.30 0.06 Symptom distress: pain, how severe –0.28 0.03 Symptom distress: appetite 0.08 0.59 Symptom distress: fatigue –0.06 0.68 © Queen’s Printer and Controller of HMSO 2007. All rights reserved. a Negative values favour I, positive values favour C. Discontinuations: Not reported Number of cycles: median of 5 cycles of mitoxantrone Health Technology Assessment 2007; Vol. 11: No. 2 151
Page 1 and 2:
A systematic review and economic mo
Page 3 and 4:
A systematic review and economic mo
Page 5 and 6:
Objectives: A systematic review was
Page 7 and 8:
Glossary and list of abbreviations
Page 9 and 10:
Glossary Absolute risk reduction Th
Page 11 and 12:
Glossary continued Expected value o
Page 13 and 14:
Glossary continued Progression-free
Page 15:
List of abbreviations ASCO American
Page 18 and 19:
xvi Executive summary of study desi
Page 20 and 21:
xviii Executive summary prednisone/
Page 23 and 24:
Description of underlying health pr
Page 25 and 26:
● Patients with severe fluid rete
Page 27 and 28:
Search strategy As stated in Chapte
Page 29 and 30:
consensus and, if necessary, a thir
Page 31 and 32:
Quantity of research available A to
Page 33 and 34:
TABLE 1 Summary of included RCTs St
Page 35 and 36:
TABLE 2 Treatment comparisons relat
Page 37 and 38:
tumour response was reported for on
Page 39 and 40:
TABLE 4 Summary results table for d
Page 41 and 42:
decrease in PSA level (51 and 39% c
Page 43 and 44:
Survival (%) 100 80 60 40 20 0 0 co
Page 45 and 46:
TABLE 8 Summary results table for d
Page 47 and 48:
TABLE 9 Grade 3 or 4 adverse events
Page 49 and 50:
Also used was the core questionnair
Page 51 and 52:
these, 69 patients had measurable t
Page 53 and 54:
Effectiveness of mitoxantrone plus
Page 55 and 56:
over to receive additional mitoxant
Page 57 and 58:
Progression-free survival It is not
Page 59 and 60:
compared with corticosteroids. The
Page 61 and 62:
statistically significant improveme
Page 63 and 64:
Summary of studies included in the
Page 65 and 66:
TABLE 19 Percentage of costs by res
Page 67 and 68:
TABLE 21 Summary of submission by S
Page 69 and 70:
TABLE 24 Other in-trial costs a bod
Page 71 and 72:
TABLE 27 Cost-effectiveness results
Page 73 and 74:
Introduction The review of cost-eff
Page 75 and 76:
TABLE 28 Regression coefficients fr
Page 77 and 78:
cancer QoL estimation. Studies whic
Page 79 and 80:
Localised Metastatic mHRPC Bennet (
Page 81 and 82:
TABLE 34 Unit costs of drugs from t
Page 83 and 84:
were assigned to the total follow-u
Page 85 and 86:
Probability cost-effective given da
Page 87 and 88:
Probability cost-effective given da
Page 89 and 90:
TABLE 43 Utility values including/e
Page 91 and 92:
was set to be 1.5 years based on th
Page 93:
Population value of implementation/
Page 96 and 97:
76 Discussion (CCI-NOV22) and least
Page 98 and 99:
78 Discussion subsequent chemothera
Page 101:
Rodolphe Perard received funding fr
Page 104 and 105:
84 References Compendium; 2004. URL
Page 106 and 107:
86 References (D) in patients (pts)
Page 108 and 109:
88 References 100. Aventis Pharma.
Page 110 and 111:
90 References low-dose prednisone i
Page 112 and 113:
92 References 180. Kozloff M, Robin
Page 114 and 115:
94 References locally advanced pros
Page 116 and 117:
96 References 251. Scholz MC, Guess
Page 119 and 120: Clinical effectiveness Searching fo
Page 121 and 122: 1. Prostatic Intraepithelial Neopla
Page 123 and 124: 19. donataxel 20. doxetal 21. doxmi
Page 125 and 126: 6. Mitozantrone.ti,ab. 7. Mitoxantr
Page 127 and 128: Texot or Trazoteva or Trixotene or
Page 129 and 130: 1. (docetaxel OR asodecel OR doxeta
Page 131 and 132: 10. (index of wellbeing or quality
Page 133 and 134: Appendix 2 Excluded studies Study d
Page 135 and 136: Study details Reason for exclusion
Page 137 and 138: Meeting: 2004 ASCO Annual Meeting C
Page 139 and 140: Studies of clinical effectiveness w
Page 141 and 142: Using the method outlined by Parmar
Page 143 and 144: Appendix 6 Data extraction tables
Page 145 and 146: Study details and Participant detai
Page 169: Study details and Participant detai
Page 175: Study details and Participant detai
Page 178 and 179: 158 Appendix 7 Ernst et al. 33 Qual
Page 181 and 182: Appendix 9 © Queen’s Printer and
Page 183 and 184: Sanofi-Aventis 61 Bloomfield et al.
Page 185: Sanofi-Aventis 61 Bloomfield et al.
Page 188 and 189: 168 Appendix 10 TABLE 51 Mean (SD)
Page 190 and 191: 170 Appendix 10 TABLE 54 Distributi
Page 192 and 193: 172 Appendix 10 TABLE 57 Mean stand
Page 194 and 195: 174 Appendix 11 TABLE 63 Drug and a
Page 196 and 197: 176 Appendix 12 Scenario: moderate
Page 198 and 199: 178 Appendix 13 ● You occasionall
Page 202 and 203: Members Chair, Professor Tom Walley
Page 204 and 205: Members Chair, Professor Bruce Camp
Page 207: Feedback The HTA Programme and the
show all

Docetaxel with prednisone or prednisolone for the treatment of ...

Create successful ePaper yourself

Delete template?

Save as template?